Read this manager's filing book
Disclosed positions
SECTORAL ASSET MANAGEMENT INC: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- CONTINEUM THERAPEUTICS
- Ticker
- CTNM
- Class
- CL A
- Reported value
- $11,925,151
- Reported amount
- 727,587
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001104659-26-096554Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| CONTINEUM THERAPEUTICS | CTNM | CL A | $11,925,151 | 727,587 | SH | None |
| SHOULDER INNOVATIONS | SI | COMMON STOCK | $8,728,654 | 430,407 | SH | None |
| ELI LILLY & CO | LLY | COM | $7,621,178 | 6,354 | SH | None |
| UNITEDHEALTH GRP INC | UNH | COM | $5,500,863 | 13,235 | SH | None |
| JOHNSON & JOHNSON | JNJ | COM | $4,626,825 | 18,218 | SH | None |
| ORUKA THERAPEUTICS INC | ORKA | COM | $3,995,903 | 41,987 | SH | None |
| BIONTECH SE | BNTX | SP ADR | $3,895,910 | 41,869 | SH | None |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $3,683,702 | 78,310 | SH | None |
| DEXCOM INC | DXCM | COM | $3,418,417 | 50,756 | SH | None |
| ARCUS BIOSCIENCES | RCUS | COM | $3,418,122 | 110,870 | SH | None |
| AMGEN INC | AMGN | COM | $3,335,125 | 9,210 | SH | None |
| SUMMIT THERAPEUTICS | SMMT | COM | $3,208,023 | 220,180 | SH | None |
| IRHYTHM HOLDINGS INC | IRTC | COM | $3,101,027 | 26,070 | SH | None |
| ABBVIE INC | ABBV | COM | $3,070,008 | 12,200 | SH | None |
| MERCK & CO INC | MRK | COM | $2,772,981 | 21,480 | SH | None |
| ARRIVENT BIOPHARMA | AVBP | COM | $2,745,954 | 79,043 | SH | None |
| VERTEX PHARMA | VRTX | COM | $2,698,237 | 5,432 | SH | None |
| ARGENX SE | ARGX | SP ADR | $2,626,517 | 2,831 | SH | None |
| GILEAD SCIENCES INC | GILD | COM | $2,605,131 | 20,620 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $2,475,290 | 23,216 | SH | None |
| TECTONIC THERAPEUTIC | TECX | COM | $2,440,934 | 71,009 | SH | None |
| INTUITIVE SURGIC INC | ISRG | COM NEW | $2,326,428 | 5,850 | SH | None |
| IMMATICS NV | IMTX | SHS | $2,278,521 | 224,928 | SH | None |
| STRYKER CORP | SYK | COM | $2,248,893 | 7,129 | SH | None |
| AVALO THERAPEUTICS INC | AVTX | COM NEW | $2,216,177 | 119,923 | SH | None |
| CRESCENT BIOPHARMA INC. | CBIO | COM | $2,183,400 | 121,300 | SH | None |
| ROIVANT SCIENCES LTD | ROIV | SHS | $2,162,329 | 61,100 | SH | None |
| IQVIA HOLDINGS INC | IQV | COM | $2,096,051 | 10,848 | SH | None |
| PULSE BIOSCIENCES INC | PLSE | COM | $1,882,728 | 67,895 | SH | None |
| DANAHER CORP | DHR | COM | $1,830,726 | 9,597 | SH | None |
| THERMO FISHER SCIENTIFIC | TMO | COM | $1,759,926 | 3,508 | SH | None |
| ABBOTT LABS | ABT | COM | $1,640,579 | 18,080 | SH | None |
| ALPHATEC HLDGS INC | ATEC | COM NEW | $1,608,035 | 185,900 | SH | None |
| BOSTON SCIENTIFIC | BSX | COM | $1,550,564 | 36,330 | SH | None |
| TRANSMEDICS GROUP INC | TMDX | COM | $1,457,919 | 21,950 | SH | None |
| CYTOKINETICS INC | CYTK | COM NEW | $1,391,153 | 16,330 | SH | None |
| REGENERON PHARMCTCLS | REGN | COM | $1,352,458 | 2,169 | SH | None |
| CVS HEALTH CORP | CVS | COM | $1,344,850 | 13,000 | SH | None |
| EDWARDS LIFESCIENCES | EW | COM | $1,341,160 | 14,826 | SH | None |
| TREVI THERAPEUTICS | TRVI | COM | $1,223,365 | 65,596 | SH | None |
| BRISTOL MYERS SQUIBB | BMY | COM | $1,218,663 | 21,150 | SH | None |
| VERA THERAPEUTICS | VERA | CL A | $1,097,337 | 25,573 | SH | None |
| COGENT BIOSCIENCES | COGT | COM | $1,034,838 | 26,740 | SH | None |
| MEDTRONIC PLC | MDT | SHS | $876,345 | 11,100 | SH | None |
| TARSUS PHARMACEUTICALS | TARS | COM | $836,158 | 13,285 | SH | None |
| KURA ONCOLOGY INC | KURA | COM | $784,136 | 71,480 | SH | None |
| CENTENE CORP DEL | CNC | COM | $770,280 | 12,000 | SH | None |
| UNITED THERAPEUTICS | UTHR | COM | $742,307 | 1,370 | SH | None |
| HINGE HEALTH INC | HNGE | CL A | $725,752 | 8,744 | SH | None |
| NEKTAR THERAPEUTICS | NKTR | COM NEW | $705,849 | 10,111 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.